Singapore Exchange Limited - Competition for SGX’s FTSE China A50 contract

24 Aug 2021
  • Hong Kong Exchanges and Clearing Limited (0388 HK, Not Rated) (HKEX) will be launching the MSCI China A50 Connect Index in October this year, filling a gap in cross-border finance.
  • This new derivative would plug a gap in financial instruments and regulations linking Mainland China with Hong Kong, potentially diverting volumes from SGX.
  • FTSE China A50 Index Futures has the largest turnover of equity index futures for the SGX, accounting for 57.3% of its total equity index futures. We estimate that it contributed 20% to its overall derivatives revenue and 10% to its overall revenue in FY21.
  • Maintain NEUTRAL with lower TP of S$10.78, from S$11.54. FY22e earnings reduced by 6.1% as we factor in lower volumes for FTSE China A50 contracts. Our TP remain pegged to 25x FY22e P/E, +2SD of its 5-year mean.

The news

HKEX has announced that it will launch a financial derivative in October this year for investors to hedge their risks of investments in China’s A-share market following green light from Hong Kong’s Securities and Futures Commission. HKEX has agreed with the MSCI to launch a US-dollar futures contract based on the MSCI China A50 Connect Index. This index tracks the performance of the 50 key Shanghai and Shenzhen stocks available via the Stock Connect.

 

The new derivative would help to plug a gap in the financial instruments and regulations that link China with Hong Kong, where the Shanghai-Hong Kong Stock Connect handles about HK$5bn a day in cross-border transactions. The A-share futures will enable offshore investors to hedge risks by taking contrarian positions to their underlying assets.

The Negatives

– Direct competition with FTSE China A50 Index Futures. The MSCI China A50 Connect Index Futures could divert trading volume away from the FTSE China A50 Index Futures on the SGX. This is the only A share futures available for offshore investors to date. The FTSE China A50 Index Futures has the largest turnover of equity index futures for the SGX, accounting for 57.3% of total equity index futures traded, up from 52.4% last year (Figure 1). Even though SGX does not provide a revenue for its China A50 contract, we estimate it contributed about 20% to its overall derivatives revenue and 10% to its overall revenue in FY21.

China’s importance in the global investment market is growing. The country’s weighting in the MSCI Emerging Markets Index increased from 18% at the end of December 2009 to 34% in August 2021. We believe growing demand for A-share futures will help to compensate for some of the volume that could be diverted to the HKEX’s MSCI China contract.

Moreover, SGX’s transition away from the MSCI to FTSE’s suite of products could potentially enhance client’s stickiness. We have seen this for its Taiwan index futures. The previous launch of a non-China related equity derivatives product by HKEX had a limited impact on SGX’s derivatives volume, as it was able to migrate to the FTSE product suite and maintain its leadership in Taiwan index contracts.

Outlook

Continued development of multi-assets to anchor long-term growth. SGX remains committed to expanding its suite of products through strategic partnerships and new product development for newly-acquired businesses.

Investing for medium term. SGX has guided for FY22 expenses of S$565-575mn, an 8.6% increase from FY21 at the mid-point. More than 50% of the increase will be for near-term investments. These include setting up FX ECN, climate-related initiatives and continued investments in BidFX and Scientific Beta.

Investment Actions

Maintain NEUTRAL with lower TP of S$10.78, from S$11.54. Our TP is still pegged to +2SD of its 5-year mean or 25x P/E (Figure 3). FY22e earnings have been reduced by 6.1% as we factor in lower volumes for its FTSE China A50 contracts. We believe the near-term impact could be cushioned by the usual adoption time of 3-5 years by global investors for the new MSCI China 

 

About the author

Terence Chua
Senior Research Analyst
Phillip Securities Research

Terence specialises in the consumer, conglomerate and industrials sector. He has over five years of experience as an analyst in the buy- and sell-side. As an institutional fund management analyst, he sat on the China-Hong Kong desk. Terence was ranked top 3 for Best Analyst under the small caps and energy category in the Asia Money poll 2018.

He graduated from the Singapore Management University with a major in Finance (Honours), and is the honoured recipient of the CFA scholarship.

Latest Reports

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com